wt-1

WT-1 A1 is an attractive target for immunotherapy in patients with pancreatic adenocarcinoma.

WT1 126-134 peptide is a WT1 polypeptide (Wilms' tumor 1 peptide) (RMFPNAPYL) that activates cytotoxic CD8 T cells to target and destroy WT1+ tumor cells. It can form stable complexes with either H-2Db (murine) or HLA-A0201 (human) molecules. The WT1 126-134 peptide/HLA-A0201 complex exhibits high affinity for humanized monoclonal antibodies (IgG1), with a dissociation constant (Kd) of 0.2 nM. This peptide can be utilized as a T cell vaccine or an antibody target.

'(Lys22)-Amyloid β-Protein (1-42) represents a mutation of the wild-type (WT) Amyloid β-Protein (1-42) peptide [1].'

Wild-type human myoregulin (wt hMLN) is a microprotein that inhibits the sarcoplasmic reticulum Ca²⁺ pump (SERCA), playing a crucial role in the regulation of calcium homeostasis in skeletal muscle [1].

WT hMLN (TFA) is a microprotein that functions as an inhibitor of the SR Ca2+ pump (SERCA), playing a crucial role in the regulation of calcium homeostasis in skeletal muscle [1].